| Original language | English (US) |
|---|---|
| Pages (from-to) | 93-112 |
| Number of pages | 20 |
| Journal | Journal of cardiac failure |
| Volume | 28 |
| Issue number | 1 |
| DOIs | |
| State | Published - Jan 2022 |
Bibliographical note
Funding Information:Dr Bhatt reports consulting fees from Sanofi Pasteur, Verve Therapeutics, and Clarivate and is supported by the National Heart, Lung, and Blood Institute T32 postdoctoral training grant T32HL007604. Dr Adler has received consulting fees from Medtronic and Abbott. Dr Bhadelia has received research grants from NIH Fogarty Center, has received speaking honoraria from Agilent Technologies and Health Industry Distributors Association. Dr Sauer has received research grant funding and consulting or speaking honoraria from Abbott, Boston Scientific, Medtronic, Edwards, PreCARDIA, and Bioventrix. Dr Solomon has received research grants from Alnylam, Amgen, AstraZeneca, Bellerophon, Bayer, BMS, Celladon, Cytokinetics, Eidos, Gilead, GSK, Ionis, Lone Star Heart, Mesoblast, MyoKardia, NIH/NHLBI, Neurotronik, Novartis, Respicardia, Sanofi Pasteur, Theracos, and has consulted for Akros, Alnylam, Amgen, Arena, AstraZeneca, Bayer, BMS, Cardior, Cardurion, Corvia, Cytokinetics, Daiichi-Sankyo, Gilead, GSK, Ironwood, Merck, Myokardia, Novartis, Roche, Takeda, Theracos, Quantum Genetics, Cardurion, AoBiome, Janssen, Cardiac Dimensions, Tenaya, Sanofi-Pasteur, Dinaqor, and Tremeau. Dr Vardeny reported research support from the National Institutes of Health and consulting with Sanofi-Pasteur Inc. Dr Lala reports speaker honoraria from Zoll Medical and Abbott. She serves on the DSMB for Suquana Medical and on an advisory board for Bioventrix. All other authors report no disclosures relevant to this article.